Laura Gombošová

Dr. Laura Gombošová


Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 February 2024 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
LGLaura Gombošová
Laura Gombošová
MSMartin Suchansky
Martin Suchansky
JKJuraj Krivuš
Juraj Krivuš
JHJarmila Hornová
Jarmila Hornová
ZHZuzana Havlíčeková
Zuzana Havlíčeková
MOMartina Ondrusova
Martina Ondrusova
(1) Background: We present the first real-world-data study on teduglutide-treated SBS patients in the Slovak Republic and the first study to enable the comparison of the effects of teduglutide treatment between the adult and pediatric populations. (2) Methods: This was a non-interventional retrospective cohort study of adult and pediatric SBS patients treated with teduglutide. Primary and secondary endpoints were the results of teduglutide use at 12 weeks and 6 months after the initiation of treatment, compared to baseline. (3) Results: Teduglutide treatment led to a statistically significant reduction in the volume of intravenous hydration, HPN caloric intake, HPN and intravenous hydration applications per week and to increased urine output in adult patients. The results in the pediatric population were similar, but not statistically significant. A complete weaning off HPN was achieved in 57.14% of all patients (50.00% of children; 62.50% of adults) after a median of 0.99 years of teduglutide treatment (1.07 and 0.98 years for children and adults, respectively). (4) Conclusions: Teduglutide treatment in SBS patients leads to considerable reduction in or even weaning off PN in both pediatric and adult patients.

30 August 2011 in Folia Microbiologica
Verified
Journal Article
Open access
PDF file
LGLaura Gombošová
Laura Gombošová
ILI. Lazúrová
I. Lazúrová
MZM. Zakuciová
M. Zakuciová
KČK. Čurová
K. Čurová
MKM. Kmeťová
M. Kmeťová
LSL. Siegfried
L. Siegfried
Escherichia coli gene fimA was the most frequent gene that occurred in the intestine of all investigated groups. All subjects with fimA gene had significantly higher values of tumor necrosis factor alpha (TNF-α) and CRP than those with other E. coli genes. There was also a tendency to increased serum interleukin (IL)-6 levels in patients carrying the fimA gene; however, no relation was observed to serum IL-8 and IL-10. Patients with Crohn’s disease had significantly higher IL-6 than those with ulcerative colitis (UC) and controls. The highest levels of TNF-α were detected in the UC group. There were no significant differences in serum IL-8 and IL-10 between all three groups. The presence of E. coli gene fimA in the large bowel of patients with IBD is related to the immunological activity of the disease which may be important from the aspect of therapeutical strategy.

1 June 2011 in Bratislava Medical Journal
Verified
Journal Article
Closed access
LGLaura Gombošová
Laura Gombošová
PJP Jarcuska
P Jarcuska
BBB Benova
B Benova
MBM Benicky
M Benicky
ILI Lazurova
I Lazurova

1 December 2008 in International Journal of Infectious Diseases
Verified
Journal Article
Closed access
MKM. Kmetova
M. Kmetova
KCK. Curova
K. Curova
LGLaura Gombošová
Laura Gombošová
MZM. Zakuciova
M. Zakuciova
ILI. Lazurova
I. Lazurova
LSL. Siegfried
L. Siegfried